This Month in JNM

March 3, 2016

Promise and challenges in RIT: Kraeber-Bodéré and colleagues offer perspective on current clinical uses and potential future applications of radioimmunotherapy and preview an article on bispecific radioimmunoconjugate therapy in this issue of JNM. Page 329

Pretargeted immuno-PET: Marquez and Lapi briefly review the advantages of bispecific targeting with antibodies, including reduction of exposure to normal organs and reliable retention of tumor accumulation, and discuss a related article in this issue of JNM. Page 332

Shortened 18F-FMISO dynamic PET: Grkovski and colleagues investigate the feasibility of kinetic modeling using shortened acquisition times in 18F-fluoromisonidazole dynamic PET, with the goal of expediting clinical implementation. Page 334

Post-RT PET in nasopharyngeal carcinoma: Zhou and colleagues report on the results of a metaanalysis of published data on the value of 18F-FDG PET/CT in identification of residual or recurrent nasopharyngeal carcinoma. Page 342

PEM interpretation for reduced counts: MacDonald and colleagues study the effects of reduced 18F-FDG injection activity on interpretation of positron emission mammography images and compare interpretations at 2 postinjection acquisition times. Page 348

PERCIST and survival after radioembolization: Michl and colleagues evaluate the prognostic accuracy of established PET response criteria in patients with liver metastases from pancreatic cancer after treatment with 90Y microspheres. Page 355

18F-FAZA PET in pancreatic cancer: Metran-Nascente et al. describe a minimally invasive technique for measuring the oxygenation status of pancreatic cancers. Page 361

68Ga-PSMA PET for lung metastases: Pyka and colleagues explore the use of a 68Ga-labeled prostate-specific membrane antigen agent in PET differentiation between pulmonary metastases and primary lung cancer in patients with prostate cancer. Page 367

Sympathetic activation and BAT: Bahler and colleagues examine the question of whether lower brown adipose tissue activity in older or overweight individuals can be explained by a lower sympathetic nervous system response to cold. Page 372

SPECT vs. CT in acute chest pain: Nabi and colleagues compare the performance of SPECT stress myocardial perfusion, optimized with stress-only imaging, with that of cardiac CT angiography in patients with acute chest pain. Page 378

Nicorandil MPI and prognosis: Fukushima and colleagues describe a technique using nicorandil stress myocardial perfusion SPECT with this hybrid adenosine triphosphate–sensitive potassium channel opener to predict major adverse cardiac events in patients with acute ischemic heart failure. Page 385

Genetics and brain 18F-FDG uptake: Watanabe and colleagues study 18F-FDG uptake on PET in monozygotic and dizygotic twins and controls to elucidate the relative effects of genetic and environmental influences on regional brain glucose metabolism. Page 392

99mTc-CXCL8 and inflammation in IBD: Aarntzen and colleagues investigate the accuracy of 99mTc-CXCL8 SPECT in detection and localization of disease activity in a prospective series of patients with inflammatory bowel disease. Page 398

Human dosimetry of 68Ga-DOTA-E[c(RGDfK)]2: López-Rodríguez and colleagues use whole-body PET to detail the biodistribution of and radiation dose from this radiolabeled dimeric αvβ3 integrin ligand as a potential agent for imaging tumor angiogenesis. Page 404

PET/MR and neurodegeneration: Tahmasian and colleagues determine whether multimodal imaging based on the network degeneration hypothesis can distinguish between different neurodegenerative syndromes. Page 410

Pulsatile-flow ventilation PET/CT: Prior and colleagues explore the performance of a novel system for reducing respiratory motion in PET/CT in inducing sustained apnea in spontaneously breathing patients. Page 416

PET/CT and PET/MR in cancer: Spick and colleagues provide an educational overview of PET/MR scanner designs, including technical and operational issues, and review the literature to determine whether cancer assessments are improved with this hybrid modality. Page 420

Affibody radionuclide pretargeting: Altai and colleagues describe mouse studies testing the hypothesis that Affibody-based bioorthogonal chemistry–mediated pretargeting can reduce radiometal accumulation in kidneys, creating preconditions for palliative radionuclide therapy. Page 431

64Cu-ATSM and pO2: Li and colleagues compare the accumulation and distribution of 64Cu-ATSM and 64CuCl2 in different tumor tissues using partial pressure of oxygen probe measurements to determine relative robustness as hypoxia markers. Page 437

Dual-receptor targeted RIT: Razumienko and colleagues describe the results of translational studies treating tumors coexpressing human epidermal growth factor receptor–2 and epidermal growth factor receptor with radiolabeled bispecific radioimmunoconjugates. Page 444

Pretargeted PET and CA19.9: Houghton and colleagues detail a pretargeting strategy that exploits the bioorthogonal reaction between transcyclooctene and tetrazine to overcome time and other challenges in PET imaging of cancers expressing carbohydrate antigen 19.9. Page 453

PET and integrin α5β1 and αvβ3: Notni and colleagues report on the use of click chemistry in developing 68Ga-aquibeprin, which is combined with 68Ga-avebetrin to produce complementary PET mapping of integrins α5β1 and αvβ3. Page 460

Imaging experimental arthritis: Terry and colleagues test fibroblast activation protein, macrophages, and integrin αvβ3 as targets for 111In-labeled imaging of response to etanercept in arthritic mice. Page 467

PET/MR tumor modeling: Divine and colleagues create a Gaussian mixture modeling pipeline to structure complementary information from 18F-FDG PET and diffusion-weighted MR imaging, separating the tumor microenvironment into compartments and longitudinally following individual compartment development. Page 473

VEGF-A–targeted fluorescence endoscopy: Tjalma and colleagues validate fluorescent tracers targeted to vascular endothelial growth factor A and epidermal growth factor receptor during ex vivo colonoscopy with a near-infrared endoscopy platform. Page 480

213Bi micro-SPECT imaging: de Swart and colleagues describe the 213Bi imaging capabilities of the Versatile Emission Computed Tomograph for simultaneous preclinical imaging of both SPECT and PET isotopes over a wide photon energy range of 25–600 keV. Page 486